Real‐world impact of non–breast cancer–specific death on overall survival in resectable breast cancer

The real‐world occurrence rate of non–breast cancer–specific death (non‐BCSD) and its impact on patients with breast cancer are poorly recognized.

[1]  J. Vandenbroucke,et al.  Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients. , 2016, Journal of the National Cancer Institute.

[2]  T. Whelan,et al.  Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27 , 2016, Breast Cancer Research and Treatment.

[3]  F. Montemurro,et al.  Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.

[4]  Steven Woloshin,et al.  Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death. , 2014, Journal of the National Cancer Institute. Monographs.

[5]  E. Bar-Meir,et al.  Second international consensus guidelines for breast cancer in young women (BCY2). , 2014, Breast.

[6]  M. Dowsett,et al.  2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial , 2013, The Lancet.

[7]  D. Altman,et al.  Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. , 2013, Journal of the National Cancer Institute.

[8]  M. Espié,et al.  6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[9]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[10]  Paul C Lambert,et al.  Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions , 2013, BMC Medical Research Methodology.

[11]  S. Hilsenbeck,et al.  Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  John M S Bartlett,et al.  Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  István Láng,et al.  Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Gelber,et al.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.

[15]  J. Woodcock,et al.  The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. , 2010, The oncologist.

[16]  Jorma Isola,et al.  Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  I. Tannock,et al.  Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Cuzick.  Primary endpoints for randomised trials of cancer therapy , 2008, The Lancet.

[19]  S. Giordano.  Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis , 2008 .

[20]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[22]  G. Barosi,et al.  Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Amadori,et al.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[25]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[26]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[27]  Michael Gnant,et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.

[28]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[29]  R. Hähnel,et al.  Oestrogen receptors revisited: long‐term follow up of over five thousand breast cancer patients , 2004, ANZ journal of surgery.

[30]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[31]  S. Devesa,et al.  Probabilities of death from breast cancer and other causes among female breast cancer patients. , 2004, Journal of the National Cancer Institute.

[32]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[33]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[34]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[35]  F. Cardoso,et al.  First international consensus guidelines for breast cancer in young women (BCY1). , 2014, Breast.

[36]  P. Neven,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2012, The New England journal of medicine.

[37]  T. Eberlein.  Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma , 2009 .

[38]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[39]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[40]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .